Torensma R - Search Results

1

Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.

Vasaturo A, Verdoes M, de Vries J, Torensma R, Figdor CG. Vasaturo A, et al. Among authors: torensma r. Immunobiology. 2015 Feb;220(2):243-8. doi: 10.1016/j.imbio.2014.11.007. Epub 2014 Nov 15. Immunobiology. 2015. PMID: 25466585 Review.

2

Targeting antigens to dendritic cells in vivo.

Tacken PJ, Torensma R, Figdor CG. Tacken PJ, et al. Among authors: torensma r. Immunobiology. 2006;211(6-8):599-608. doi: 10.1016/j.imbio.2006.05.021. Epub 2006 Jul 7. Immunobiology. 2006. PMID: 16920498 Review.

3

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Tacken PJ, et al. Among authors: torensma r. Nat Rev Immunol. 2007 Oct;7(10):790-802. doi: 10.1038/nri2173. Nat Rev Immunol. 2007. PMID: 17853902 Review.

4

Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.

Bakdash G, Buschow SI, Gorris MA, Halilovic A, Hato SV, Sköld AE, Schreibelt G, Sittig SP, Torensma R, Duiveman-de Boer T, Schröder C, Smits EL, Figdor CG, de Vries IJ. Bakdash G, et al. Among authors: torensma r. Cancer Res. 2016 Aug 1;76(15):4332-46. doi: 10.1158/0008-5472.CAN-15-1695. Epub 2016 Jun 20. Cancer Res. 2016. PMID: 27325645

5

Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.

de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ. de Vries IJ, et al. Among authors: torensma r. Clin Cancer Res. 2003 Nov 1;9(14):5091-100. Clin Cancer Res. 2003. PMID: 14613986

6

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody.

Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG. Tacken PJ, et al. Among authors: torensma r. Blood. 2005 Aug 15;106(4):1278-85. doi: 10.1182/blood-2005-01-0318. Epub 2005 May 5. Blood. 2005. PMID: 15878980 Free article.

7

Dendritic cell interaction with Candida albicans critically depends on N-linked mannan.

Cambi A, Netea MG, Mora-Montes HM, Gow NA, Hato SV, Lowman DW, Kullberg BJ, Torensma R, Williams DL, Figdor CG. Cambi A, et al. Among authors: torensma r. J Biol Chem. 2008 Jul 18;283(29):20590-9. doi: 10.1074/jbc.M709334200. Epub 2008 May 15. J Biol Chem. 2008. PMID: 18482990 Free PMC article.

8

No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation.

Tacken PJ, Joosten B, Reddy A, Wu D, Eek A, Laverman P, Kretz-Rommel A, Adema GJ, Torensma R, Figdor CG. Tacken PJ, et al. Among authors: torensma r. J Immunol. 2008 Jun 1;180(11):7687-96. doi: 10.4049/jimmunol.180.11.7687. J Immunol. 2008. PMID: 18490772

9

Mesenchymal stromal cells: tissue engineers and immune response modulators.

van den Berk LC, Figdor CG, Torensma R. van den Berk LC, et al. Among authors: torensma r. Arch Immunol Ther Exp (Warsz). 2008 Sep-Oct;56(5):325-9. doi: 10.1007/s00005-008-0036-z. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18836860 Free article. Review.

10

Ovarian cancer creates a suppressive microenvironment to escape immune elimination.

Yigit R, Massuger LF, Figdor CG, Torensma R. Yigit R, et al. Among authors: torensma r. Gynecol Oncol. 2010 May;117(2):366-72. doi: 10.1016/j.ygyno.2010.01.019. Epub 2010 Feb 9. Gynecol Oncol. 2010. PMID: 20144842 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Search Page

Filters